exoxemis.com Open in urlscan Pro
72.52.158.167  Public Scan

Form analysis
0 forms found in the DOM

Text Content

medinfo@exoxemis.com

 * About Us
   * Vision
   * Intellectual
 * Technology
 * Indications
 * Collaboration
   * Parter
 * Publications
   * Literature
 * Contact Us

 * 

 * About Us
   * Vision
   * Intellectual
 * Technology
 * Indications
 * Collaboration
   * Parter
 * Publications
   * Literature
 * Contact Us

   
 * Welcome to EXOXEMIS
   Exoxemis is a biomedical research company
   Focused on the study and commercialization of Zempia®, our trade name for a
   topical biological antiseptic system utilizing Myeloperoxidase (MPO).
   
   
 * Welcome to EXOXEMIS
   Exoxemis is a biomedical research company
   Focused on the study and commercialization of Zempia®, our trade name for a
   topical biological antiseptic system utilizing Myeloperoxidase (MPO).
   









HUMAN CLINICAL TRIALS

Exoxemis has completed a placebo controlled, randomized, international, Pivotal,
Phase III, human clinical trial with 250 human subjects in each arm, at 25 U.S.
and 5 Israeli sites. This study provides direct evidence that Zempia® is safe
for use in open wounds—it does not interfere with normal wound healing.



ABOUT ZEMPIA®

While Zempia® has not been approved by the FDA for human use, Zempia® has
undergone extensive in vitro, efficacy studies—laboratory and animal
testing—which provides direct evidence that Zempia®…..




ACTION OF ZEMPIA®

 * 

Has broad microbicidal activity against all wound pathogens; kills antibiotic
resistant bacteria; is effective in killing gram-negative and gram-positive
bacteria, viruses, spores, yeast and fungi.

 * Does not harm tissue or blood cells; preferentially selects and binds to
   pathogens.

 * Does not cause local irritation or sensitization.
 * Is not systemically absorbed (thereby eliminating systemic toxicity).

 * Has microbicidal activity in wound environments with blood and/or exudate
   where most other antiseptics in use today (except for silver) are inactivated
   by miniscule amounts of blood. Silver however is a small molecule and can be
   absorbed—hence has potential toxic side effects although no safety or
   evidentiary studies on silver or any other antiseptic in use today have been
   conducted and are on file at FDA.
 * 
 * Inactivates endotoxin and Lipid A. Other antiseptics kill bacteria but they
   leave the endotoxins that cause sepsis. Zempia® could potentially be a
   breakthrough in preventing sepsis.

Read More


E-101 SOLUTION (ZEMPIA®) DEMONSTRATES VIRICIDAL
PROPERTIES AGAINST CORONAVIRUS IN MUCIN.

EPOSTER WITH AUDIO AND SLIDE PRESENTATION FROM THE
THE ESCMID CONFERENCE ON CORONAVIRUS DISEASE (ECCVID)
SEPTEMBER 2020



PRESENTATION HERE





FOR IMMEDIATE RELEASE

GROUNDBREAKING RESEARCH POINTS TOWARDS ZEMPIA®
AS A PROPOSED NEW WEAPON IN MEDICINE’S ARMAMENTARIUM TO FIGHT SEPSIS

Myeloperoxidase and Eosinophil Peroxidase Conclusively
Shown to Inactivate Endotoxin and Lipid A.

Jackson T. “Steve” Stephens, Founder and CEO of Exoxemis, Inc.
(www.exoxemis.com) announced the ublication of a peer reviewed article, which he
co-authored with Dr. Robert C. Allen just published in the Journal of Immunology
Research titled Myeloperoxidase and Eosinophil Peroxidase Inhibit Endotoxin
Activity and Increase Mouse Survival in a Lipopolysaccharide Lethal Dose 90%
Model. Full article text available here.

This is a ground breaking study relative to the further investigation and
testing of Zempia®, our trade name for myeloperoxidase (MPO), to combat sepsis,”
commented Mr. Stephens. “Our study utilized the Limulus amebocyte lysate (LAL)
test which is the definitive test recognized by the FDA with regard to detecting
endotoxins. Additionally, the mouse lethal dose 90% (LD90) survival model
testing provided ‘unquestionably significant’ in-vivo data that demonstrated MPO
increased survival in mice administered MPO with an otherwise lethal dose of
endotoxin.”

Antibiotics and antiseptics can kill bacteria but they can leave behind toxins
(poisons). In the case of Gram-negative bacteria release of residual
lipopolysaccharide results in potentially lethal endotoxemia. “Our extensive
in-vivo and in-vitro testing over the last twenty-seven years has given us
direct evidence that Myeloperoxidase (MPO) when mixed with a
substrate solution containing Glucose Oxidase plus glucose produces hypochlorous
acid and singlet oxygen which, in addition to killing pathogens, inactivates
endotoxins from gram negative bacteria and other toxins from gram-positive
bacteria. This new study (just released) demonstrates that MPO alone (in the
absence of hypochlorite and singlet oxygen
Production) provides nonenzymatic protection against endotoxin, i.e.,
lipopolysaccharide (LPS) as well as its toxic lipid A component. This is a huge
discovery relative to combatting gram negative sepsis.”

According to the CDC (Center for Disease Control and Prevention) “at least 1.7
million adults in America develop sepsis.Nearly 270,000 Americans die as a
result of sepsis. 1 in 3 patients who die ina hospital have sepsis” The National
Institutes of Health estimates that more people die from sepsis than from
prostate cancer, breast cancer and AIDS combined.

Exoxemis is a biomedical research company focused on the research and
development of Zempia®, the company’s trade name for Myeloperoxidase. “Exoxemis
is the only biomedical research company in the world that has been able to make
MPO in large, pure quantities at a price that makes it suitable for commercial
use either in conjunction with a medical
device or as a therapeutic,” said Mr. Stephens.

Exoxemis has completed three Phase | and one Phase III human clinical trial with
250 human subjects in each arm, at 25 U.S. and 5 Israeli sites, A primary safety
end point of the Phase Ill study was to compare Zempia® (referred to as E-101 in
the study) to saline. The safety conclusions of this study in part conclude:
“This E-101 Solution-related safety profile
demonstrates no increased documentation of abnormal laboratory tests (i.e.,
serum chemistry, hematological, urinalysis or coagulation test), physical
examination (primary intent wound healing followed for up to six months after
surgery), quality of life assessments, tolerability or serious event reporting
among E-101 Solution treated subjects compared to saint ih
this protocol.” The Phase III Clinical Report Summary (CRS) is on file with the
FDA and is available to interested parties.

The prior in vitro, efficacy studies—laboratory and animal testing—have
generated direct evidence that Zempia®:

 * Has broad microbicidal activity against all wound pathogens; kills antibiotic
   resistant bacteria; is effective in killing gram-negative and gram-positive
   bacteria, viruses, and spores, yeast, and fungi.
 * Does not harm tissue or blood cells because it selects for, and binds to,
   pathogens.
 * Does not cause local irritation or sensitization
 * Is not systemically absorbed (thereby eliminating systemic toxicity)
 * Has microbicidal activity in wound environments with blood and/or exudate
   where most other antiseptics in use today (except for silver) are inactivated
   by miniscule amounts of blood. Silver, however, is a small ion and can be
   absorbed—hence has potential toxic side effects although no evidentiary
   safety or efficacy studies on silver or any other antiseptic in use today
   have been conducted and are on file at FDA.
 * Inactivates endotoxin and its highly toxic component Lipid A. Other
   antiseptics kill bacteria but they can leave the endotoxins that cause
   sepsis, Zempia is a breakthrough in preventing sepsis.

Exoxemis holds a number of method and composition Patents throughout the world,
and a number of patents are currently pending. In addition, the company has
registered Zempia® and has pending trademarks throughout the world.

An exclusive licensing agreement is available for Zempia® for further Study and
testing with applications in a number of potential markets: for use in
preventing sepsis, in conjunction with large joint implants; urinary catheters;
dental implants and oral surgeries; for use in the ER, in wound treatments,
colorectal, HEENT, Plastics/Burn-really in any surgery or
condition involving an open wound or normal flora environment that is
susceptible to infection. This includes skin care, dermatology, even cosmetics.

“We are also interested in pursuing further investigation and testing with
regard to the use of Zempia® to counter biological warfare. Our tests show that
Zempia® has broad antimicrobial action against bacteria that medics and first
responders might not normally encounter—to help protect them while administering
medical treatment and to contain the biological threat when every second
counts,” said Mr. Stephens.

Further research and test data on Zempia®, E-101 and MPO is available by
visiting the Exoxemis website: www.exoxemis.com

JACKSON T. “STEVE” STEPHENS
FOUNDER & CEO


PARTNER WITH EXOXEMIS

Today, Exoxemis, Inc. is well qualified to partner with a medical device or
pharmaceutical company to conduct further testing, obtain regulatory approval
and to more quickly optimize Zempia® market share. An exclusive licensing
agreement is available for Zempia® for several applications in a number of
potential markets:  for use in conjunction with large joint implants; urinary
catheters; dental implants and oral surgeries; for use in the ER, in wound
treatments, colorectal, HEENT, Plastics/Burn. . . .really in any surgery or
condition involving an open wound that is susceptible to infection. This
includes skin care, dermatology, even cosmetics. We believe that Zempia® could
be an effective weapon to fight AMR and HAI’s infections that are now a crisis
and plaguing our hospital systems.



“WE’RE STILL IN THE AGE OF THE TELEGRAPH WITH REGARD TO TOPICAL ANTISEPTIC R&D.
WHILE FURTHER TESTING AND APPROVAL FOR ZEMPIA® IS NECESSARY, WE’RE VERY EXCITED
ABOUT IT’S MANY COMMERCIAL APPLICATIONS.”

Jackson T. “Steve” Stephens
Founder & CEO

In 1919, Alexander Fleming proved that carbolic acid and other antiseptics
indiscriminately kill pathogens as well as healthy tissue including the white
blood cells that offer the body’s own defense mechanism against infection
Researchers in the field of antiseptics have made futile attempts to balance
pathogenic, germ cell killing with the sparing of human cells. Adding to the
problem, it was also discovered that antiseptic germ-killing properties are
inactivated in small amounts of human blood but still kill human cells.

The unsatisfactory problem with antiseptics was ignored for decades primarily
due to the effective use of antibiotics. After decades of over-prescribing
antibiotics and the dilution of antiseptics, germs have built up a resistance to
both topical and systemic agents meant to kill them. 



INTRODUCTION TO ZEMPIA®







INVESTIGATION OF ANTI-TUMOR

Investigation of anti-tumor activity of porcine myeloperoxidase for urothelial
carcinoma of the bladder.


AACR Abstract
Stay tuned for additional peer reviews and news—more updates to come.

Privacy Policy| Terms of Use © 2022 Exoxemis | Hosted by Elevated